Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The Australia molecular diagnostics market was valued at USD 10.32 Billion in 2025 and is expected to grow at a CAGR of 7.90%, reaching USD 22.07 Billion by 2035. The market growth benefits from established healthcare infrastructure, increasing adoption of precision medicine, and rising demand for rapid and accurate testing. The expanding use of genomic technologies, point-of-care platforms, and molecular testing in oncology and infectious diseases is expected to support market expansion throughout the forecast period.
Compound Annual Growth Rate
7.9%
Value in USD Billion
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Molecular diagnostics supports modern healthcare by enabling the detection of genetic, infectious, and disease-related biomarkers with high accuracy. Its applications across disease diagnosis, treatment selection, and monitoring continue to strengthen its relevance in clinical practice. The market was valued at USD 10.32 Billion in 2025. The market is supported by growing demand for accurate and timely diagnostic testing, increasing adoption of advanced laboratory technologies, and the expanding use of molecular testing across healthcare settings. Market development is also influenced by improvements in diagnostic infrastructure, increasing disease awareness, and the integration of innovative testing technologies.
|
Analysis Type |
Factors |
Example |
|
Market Drivers |
Rising neurological disease burden is increasing demand for accurate molecular diagnostics for disease characterization, genetic assessment, and treatment planning. |
Approximately 4.5 million Australians were living with neurological conditions in 2025, supporting greater demand for advanced diagnostic testing. |
|
Market Restraints |
Complex molecular testing requirements and shortages of specialized laboratory expertise can increase costs and restrict adoption across smaller healthcare facilities. |
Specialized infrastructure, trained personnel, and technical expertise can create implementation barriers for laboratories with limited resources. |
|
Market Opportunities |
Expanding microbiome diagnostics is creating opportunities for molecular testing in gastrointestinal disease assessment and standardized microbiome profiling. |
In August 2026, Genetic Analysis placed its GA-map® Dysbiosis Test at Sydney’s Centre for Digestive Diseases. |
The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.
Rising Neurological Disease Burden Supports Molecular Diagnostic Demand
The growing burden of neurological conditions is increasing the need for accurate and timely molecular diagnostics for disease characterization, genetic assessment, and treatment planning. According to the Australian Institute of Health and Welfare (AIHW), an estimated 4.5 million Australians, representing approximately 16.5% of the population, were living with neurological conditions in 2025. Migraine alone affected approximately 3.9 million people. This substantial disease burden is expected to encourage greater diagnostic evaluation and adoption of advanced testing technologies, supporting market expansion.
Complex Testing Requirements and Skilled Workforce Constraints May Limit Market Expansion
The adoption of molecular diagnostics can be constrained by the need for specialized laboratory infrastructure, trained personnel, and technical expertise to perform and interpret complex molecular tests. These requirements can increase operational costs and create implementation challenges, particularly for smaller laboratories and healthcare facilities with limited resources. Variations in laboratory capabilities and access to specialized testing may further slow the consistent adoption of advanced molecular diagnostic technologies, potentially limiting the pace of market expansion.
Expanding Microbiome Diagnostics Creates New Growth Potential
The increasing clinical application of microbiome-based testing creates scope for expanding molecular diagnostic solutions beyond conventional disease detection. Greater understanding of the relationship between gut microbiota and gastrointestinal disorders is supporting the introduction of specialized molecular testing platforms. For instance, in August 2026, Genetic Analysis announced the first Australian placement of its GA-map® Dysbiosis Test at the Centre for Digestive Diseases in Sydney, providing clinicians with standardized microbiome profiling capabilities. Such developments could broaden clinical applications and support future market growth.
The market is witnessing several trends, including expanded distribution networks, advanced molecular platforms, and greater access to innovative diagnostic technologies.
Expanding Access to Advanced Molecular Diagnostic Technologies Is Likely to Enhance Market Growth
The market is increasingly characterized by partnerships that improve access to advanced molecular diagnostic instruments, reagents, and laboratory technologies. For instance, in June 2024, Abacus dx announced a commercial partnership with Roche to distribute molecular diagnostics hardware and reagents in Australia, including the LightCycler® systems and MagNA Pure platforms. Such collaborations can strengthen technology availability across research and laboratory settings, support broader adoption of advanced testing solutions, and contribute to market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Infectious Diseases Segment Is Positioned to Lead the Market
The market is segmented by application into oncology, pharmacogenomics, infectious diseases, genetic testing, neurological diseases, cardiovascular diseases, microbiology, and others. Among these, infectious diseases is expected to lead, supported by the substantial burden of infectious conditions and continued demand for rapid and accurate pathogen detection. According to the Australian Institute of Health and Welfare (AIHW), more than 557,000 hospitalizations were attributed to infectious diseases in 2024, while COVID-19 accounted for 43,950 DALYs. This persistent disease burden is expected to sustain demand for molecular testing and support segment growth.
The key features of the market report include funding and investment analysis, and strategic initiatives by leading players. The major companies in the market are as follows:
Cepheid Inc. develops molecular diagnostic solutions centered on its GeneXpert® sample-to-answer PCR platform. Its portfolio includes GeneXpert systems with touchscreen interfaces, GeneXpert Infinity, and GeneXpert Xpress, supporting rapid and scalable molecular testing. The company contributes to the market by providing PCR-based platforms designed to expand accessible, automated molecular testing across healthcare settings.
F. Hoffmann-La Roche AG provides molecular diagnostic technologies, including the cobas® 5800 system for automated, integrated PCR-based nucleic acid testing. The platform combines instrumentation, consumables, reagents, and data management within standardized workflows. Roche participates in the market through its portfolio of automated molecular testing systems supporting laboratory efficiency and scalable diagnostic testing.
Thermo Fisher Scientific Inc. provides molecular testing technologies, including the Applied Biosystems QuantStudio Absolute Q Digital PCR System, assays, kits, reagents, and consumables. Its digital PCR portfolio supports applications such as rare mutation detection, gene expression analysis, and copy number variation. The company contributes to the Australia molecular diagnostics market through advanced PCR-based molecular analysis solutions.
Eiken Chemical Co., Ltd. develops healthcare technologies and emphasizes research and development, quality, and access to medical solutions. However, the provided information does not identify a specific molecular diagnostic product or Australia-related activity. Therefore, its direct involvement in the market cannot be established from the supplied source alone.
Other key players in the market include ILLUMINA, INC, BioMérieux SA, QIAGEN N.V., and ABBOTT LABORATORIES.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product and Services
The market is categorized according to the products and services supporting molecular testing workflows. Increasing diagnostic requirements, laboratory modernization, and the integration of molecular testing into healthcare practices are contributing to market development and expanding the utilization of these solutions.
Market Breakup by Test Location
Test-location segmentation reflects the diverse settings through which molecular diagnostic testing is delivered in Australia. The growing emphasis on timely diagnosis, accessibility, patient convenience, and decentralized healthcare is influencing the adoption and utilization of molecular diagnostic solutions across different testing environments.
Market Breakup by Technology
The Australia molecular diagnostics market encompasses various technological approaches used for molecular detection and analysis. Advances in diagnostic capabilities, automation, testing accuracy, and workflow efficiency are supporting technological development and facilitating broader incorporation of molecular diagnostic methods into clinical and laboratory practices.
Market Breakup by Application
Application-based segmentation reflects the expanding role of molecular diagnostics across healthcare in Australia. Increasing requirements for accurate disease detection, personalized treatment strategies, early diagnosis, and molecular characterization are contributing to the wider application of these technologies across diverse clinical areas.
Market Breakup by End User
The market is segmented according to the healthcare and diagnostic organizations that utilize molecular testing solutions in Australia. Increasing testing volumes, improvements in laboratory infrastructure, and greater integration of molecular diagnostics into healthcare pathways are supporting utilization across end-user settings.
This report is developed through a robust mixed-methods research design combining:
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product and Services |
|
| Breakup by Test Location |
|
| Breakup by Technology |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.